1.57

2.48% -0.04

After Hours: 1.56 -0.01 -0.64%

Regulus Therapeutics Inc (RGLS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Regulus Therapeutics Inc stock is traded at $1.57, with a volume of 110.48K. It is down -2.48% in the last 24 hours and down -6.55% over the past month. Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Previous Close:

$1.61

Open:

$1.56

24h Volume:

110.48K

Relative Volume:

0.22

Market Cap:

$101.47M

Revenue:

Net Income/Loss:

$-30.04M

P/E Ratio:

-0.929

EPS:

-1.69

Net Cash Flow:

$-27.38M

1W Performance:

-4.56%

1M Performance:

-6.55%

6M Performance:

-45.49%

1Y Performance:

+14.60%

1-Day Range:

$1.52

$1.62

1-Week Range:

$1.50

$1.68

52-Week Range:

$1.08

$3.79

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name

Regulus Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

858-202-6300

Address

4224 CAMPUS POINT COURT, SAN DIEGO, CA

Employee

Twitter

@regulusrx

Next Earnings Date

2024-08-06

Latest SEC Filings

RGLS's Discussions on Twitter

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-02-24	Initiated	Oppenheimer	Outperform
Mar-18-24	Initiated	Leerink Partners	Outperform
Mar-28-18	Initiated	B. Riley FBR, Inc.	Neutral
Jan-05-18	Initiated	Leerink Partners	Outperform
Jun-13-17	Reiterated	Chardan Capital Markets	Buy
Mar-06-17	Reiterated	Wedbush	Outperform
Jan-30-17	Downgrade	Needham	Buy → Hold
Jan-30-17	Downgrade	Wells Fargo	Outperform → Market Perform
Dec-07-16	Reiterated	Chardan Capital Markets	Buy
Nov-02-16	Reiterated	Needham	Buy
Jul-25-16	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	FBR Capital	Outperform
Jun-28-16	Reiterated	Needham	Buy
Jun-07-16	Reiterated	Chardan Capital Markets	Buy
Apr-13-16	Initiated	Chardan Capital Markets	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Jun-09-15	Initiated	Guggenheim	Buy
Apr-21-15	Resumed	FBR Capital	Outperform
Nov-24-14	Initiated	Deutsche Bank	Buy
Aug-07-14	Reiterated	FBR Capital	Outperform
Aug-14-13	Reiterated	Needham	Buy

View All

Regulus Therapeutics Inc Stock (RGLS) Latest News

Sep 28, 2024

Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by CVI Holdings LLC - MarketBeat

Sep 28, 2024

Sep 24, 2024

ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World

Sep 24, 2024

Sep 23, 2024

Investing in Regulus Therapeutics Inc (RGLS) Is Getting More Attractive - Knox Daily

Sep 23, 2024

Victory Capital Management Inc. Has $645,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Sep 23, 2024

Sep 19, 2024

Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by StockNews.com - Defense World

Sep 19, 2024

Sep 17, 2024

Regulus Therapeutics (NASDAQ:RGLS) Upgraded to "Sell" by StockNews.com - MarketBeat

Sep 17, 2024

Sep 11, 2024

Oppenheimer’s latest rating for RGLS stock - Knox Daily

Sep 11, 2024

Sep 09, 2024

RGLS stock rated an Outperform by Oppenheimer - Knox Daily

Sep 09, 2024

Gaining Ground: Regulus Therapeutics Inc (RGLS) Closes Lower at 1.46, Down -6.41 - The Dwinnex

Sep 09, 2024

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 09, 2024

Sep 06, 2024

Regulus Therapeutics (NASDAQ:RGLS) Raised to Sell at StockNews.com - MarketBeat

Sep 06, 2024

Sep 05, 2024